期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

应用分子靶向治疗的时机选择 被引量：8

Proper Timing of Apply Molecular-targeted Therapy
下载PDF
导出
摘要 分子靶向药物的出现显示出肿瘤治疗传统模式的重要进展。与传统放疗、化疗相比,分子靶向治疗因其特异性高、不良反应轻微,在恶性肿瘤个体化治疗中扮演重要角色。十五年来,分子靶向药物的出现,给肿瘤的治疗模式带来重大改变,也给临床医生带来新的挑战。准确把握分子靶向药物应用时机,获得最大临床效果,已成为肿瘤治疗领域关注热点。本文就非小细胞肺癌、消化系统肿瘤、乳腺癌、肾癌治疗中分子靶向药物如何选择应用时机进行阐述。 The development of molecule-targeted therapy is a major breakthrough in the treatment of cancer. Compared with radiotherapy and chemotherapy, molecule-targeted therapy perform an important role in individually tailored cancer therapy because of the lower toxicity and higher efficiency. Over the recent 15 years, the emergence of molecule-targeted therapy has brought great change to treatment of cancer, and also brought challenges to clinician. The timing of using the molecular-targeted therapy has become a heatedly-discussed issue. This review illustrated the issue from the perspective of molecular targeted therapies which were recommended for the cure o[ non small cell lung cancer, breast cancer, malignancies in digestive system and kidney cancer.
作者 张凯 赵瑞景 陈连刚 朱铁年
机构地区 白求恩国际和平医院肿瘤科 河北医科大学
出处 《医学与哲学（B）》 2014年第1期46-48,共3页 Medicine & Philosophy(B)
基金 国家自然科学基金 项目编号:81071846 河北省自然科学基金 项目编号:H2013505059 河北省科技厅国际合作项目 项目编号:12396107D 吴阶平基金 项目编号:320.6750.12604
关键词 肿瘤分子靶向药物 非小细胞肺癌 乳腺癌 消化系统肿瘤 肾癌 molecule-targeted drugs, non-small cell lung cancer, breast cancer, malignancies in digestive system, kidney cancer
分类号 R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献24

  • 1李宁,段向红,陈小兵,王新锋,罗素霞.靶向治疗——渐行渐近[J].医学与哲学（B）,2012,33(6):13-15. 被引量：4
  • 2Zhou C,Wu Y L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-pos- itive non-small cell lung cancer (OPTIMAL, CTONG-0802) : a mul ticentre,open-label, randomised, phase 3 study [J]. Lancet Oncol, 2011,12(8) :735-742.
  • 3Wu Y L,Fukuoka M,Mok T S,et al. Tumor response and health- related quality of life in clinically selected patients from Asia with advanced non small-cell lung cancer treated with first-line gefitinib: post hoe analyses from the IPASS study [J]. Lung Cancer,2013,81 (2) :280-287.
  • 4Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as mainte- nance therapy in patients with locally advanced or metastatic non- smalFcell lung cancer (INFORM: C-TONG 0804): a multicentre, double-blind randomised phase 3 trial [ J]. Lancet Oneol, 2012,18 (5) :466-475.
  • 5Casaluce F, Sgambato A, Maione, et al. ALK inhibitors: a new tar- geted therapy in the treatment of advanced NSCLC [J]. Targeted Oncol,2013,8(1) :55-67.
  • 6Crystal A S, Shaw A T. New targets in advanced NSCLC: EML4- ALK [J]. Clin Adv Hematol Oncol,2011,9(3) :207-214.
  • 7Slamon D J,Clark G M,Wong S G,et al. Human breast cancer:cor- relation of relapse and survival with amplification of the HER-2/ neu oncogene [J]. Science, 1987,235 (4785) : 177- 182.
  • 8Gianni L,Dafni U,Gelber R D,et aI. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer:a 4-year follow-up of a randomised controlled trial [J]. Lancet Oncol, 2011,12 (3) : 236- 244.
  • 9Perez E A, Suman V J, Davidson N E, et al. Sequential versus con- current trastuzumab in adjuvant chemotherapy for breast cancer [J]. J Clin Oncol,2011,29(34) :4491-4497.
  • 10Slamon D, Eiermann W,Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer [J]. N Engl J Med,2011,365(14): 1273-1283.

二级参考文献20

  • 1唐平章,高丽.多学科协作时代的头颈肿瘤治疗[N].中国医学论坛报,2010-04-01(B8).
  • 2Van Cutsem E, Kohne C H, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med,2009,360(14) :1408--1417.
  • 3Van Cutsem E, Kohne C H, Lang I, et al. Cetuximab plus irinotecan, fluorouracil and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival accord ing to tumor KRAS and BRAF mutatuion status[J]. J Clin Oncol, 2011,29(15) :2011--2019.
  • 4Bokemeyer C, Bondarenko I, Hartmann J T, et al. KRAS status and efficacy of firstline treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience[J]. J Clin Oncol, 2008,26:abstr 4000.
  • 5Maughan T S, Adams R A, Smith C G, et al. Addition of cetux- imab to oxaliplatin-- based first-- line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial[J]. Lancet, 2011, 377 (9783) : 2103-2114.
  • 6Perez E A, Romond E H, Suman V J, et al. Four-- year follow- up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2 positive breast cancer: joint a- nalysis of data form NCCTG N9831 and NSABP B-31[J]. J Clin Oncol,2011,29(25) :3366-3373.
  • 7Gianni L,Eiermann W, Semiglazov V, et al. Neoadjuvant chemo therapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2--positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2--negative cohort [J]. Lancet, 2010,375:377-384.
  • 8徐瑞华,王志强.大肠癌分子靶向治疗[J].中国临床肿瘤学进展,2011:261-268.
  • 9Hurwitz H, Fehrenbacher L,Novotny W, et al. Bevacizumab plus iri- notecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J].N Engl J Med, 2004,350(23) ,2335--2342.
  • 10Hochster H S, Hart L L, Ramanathan R K, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevaeizumab as first-line treatment of metastatic colorectal canc- er: results of the TREE study[J]. J Clin Oncol, 2008, 26(21): 3523- 3529.

共引文献3

同被引文献108

  • 1Bardia A,Baselga J.Neoadjuvant therapy as a platform for drug development and approval in breast cancer[J].Clin Cancer Res,2013,19(23):6360-6370.
  • 2Chen Y J,Yeh M H,Yu M C,et al.Lapatinib induced NFkappa B activation sensitizes triple-negative breast cancer cells to proteasome inhibitors[J].Breast Cancer Res,2013,15 (6):R108.
  • 3Rakha E A,El Sayed M E,Green A R,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32.
  • 4Wang L,Zhang Q,Zhang J,et al.PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib[J].BMC Cancer,2011,15(11):248-257.
  • 5Jones N,Bonnet F,Sfar S,et al.Comprehensive analysis of PTEN status in breast cardnomas[J].Int J Cancer,2013,133(2):323-334.
  • 6Inanc M,Ozkan M,Karaca H,et al.Cytokeratin 5/6,oMet expressions,and PTEN loss prognostic indicators in triple negative breast cancer[J].Med Oncol,2014,31 (1):801.
  • 7Perez E A,Dueck A C,McCullough A E,et al.Impact of PTEN protein expression on benefit from adjuvant trastuzumab in earlystage human epidermal growth factor receptor 2 positive breast cancer in the North Central Cancer Treatment Group N9831 trial[J].J ClinOncol,2013,31(17):2115-2122.
  • 8Tanic N,Milovanovic Z,Tanie N,et al.The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients[J].Cancer Biol Ther,2012,13(12):1165-1174.
  • 9Alsner J,Jensen V,Kyndi M,et al.A comparison between p53 accumulation determined by immunohistochemistry and Tp53 mutations as prognostic variables in tumors from breast cancer patients[J].Acta Oncol,2008,47(4):600-607.
  • 10Fernandez-Cuesta L,Anaganti S,Hainaut P,et al.Estrogen levels act as a rheostat on p53 levels and modulate p53 dependent respon ses in breast cancer cell lines[J].Breast Cancer Res Treat,2011,125(1):35-42.

引证文献8

二级引证文献33

医学与哲学（B）
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部